AstraZeneca stock: FDA approves Imfinzi bladder regimen
Published on 11/18/2026 at 10:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSFDA approval expands bladder cancer use
- The FDA cleared a perioperative Imfinzi regimen with enfortumab vedotin for eligible patients with muscle-invasive bladder cancer.
- The VOLGA Phase III trial showed lower risks of recurrence and death versus the comparator regimen.
- Regulatory applications based on the trial remain under review in the European Union, Japan and other countries.
On November 16, 2026, the US Food and Drug Administration approved AstraZeneca's Imfinzi in combination with enfortumab vedotin before surgery, followed by Imfinzi monotherapy, for adults with muscle-invasive bladder cancer who are ineligible for or have refused cisplatin-based chemotherapy. AstraZeneca reported the decision in a Form 6-K filing with the SEC.
AstraZeneca stock traded at 165.00 euros on Lang & Schwarz at 10:09 CET on Wednesday, November 18, 2026.
VOLGA results support the approval
The approval covers a perioperative treatment sequence. Patients receive three cycles of Imfinzi and enfortumab vedotin before radical cystectomy, followed by nine cycles of Imfinzi as adjuvant monotherapy. The regimen is aimed at patients for whom cisplatin-based chemotherapy is unsuitable or has been declined.
The decision was based on the Phase III VOLGA trial, which enrolled 695 patients across 182 centres in 25 countries. In a planned interim analysis, the Imfinzi combination reduced the risk of disease progression, recurrence, not undergoing surgery or death by 49% versus radical cystectomy with or without approved adjuvant treatment. The event-free survival hazard ratio was 0.51, with a 95% confidence interval of 0.38 to 0.67.
The trial also showed a 42% reduction in the risk of death, based on an overall survival hazard ratio of 0.58 and a 95% confidence interval of 0.40 to 0.83. At two years, 64% of patients receiving the Imfinzi combination remained alive and event-free, compared with 45% in the comparator arm. Overall survival at two years was 78% for the Imfinzi combination and 69% for the comparator.
Regulatory expansion remains ahead
AstraZeneca said the safety and tolerability profile of the combination was consistent with the known profiles of the individual medicines, with no new safety signals identified. Grade 3 and 4 adverse events occurred in 64% of patients in the Imfinzi combination group and 44% of patients in the comparator group. Patient-reported quality of life was maintained after surgery.
The US decision adds a third bladder cancer indication for Imfinzi in two years, according to AstraZeneca. The company said regulatory applications based on the VOLGA results remain under review in the European Union, Japan and several other countries. Those decisions could determine how broadly the regimen contributes to the oncology portfolio beyond the US market.
The approval strengthens AstraZeneca's position in earlier-stage bladder cancer treatment and gives physicians an option for a group that has historically faced limited choices because of cisplatin ineligibility. For investors, the commercial importance will depend on uptake, treatment duration, reimbursement and the outcome of the remaining regulatory reviews.
AstraZeneca stock at a glance
- Company: AstraZeneca PLC
- ISIN: GB0009895292
- WKN: 886455
- Primary listing: London Stock Exchange
- Ticker: AZN
- Lang & Schwarz quote: 165.00 euros on Wednesday, November 18, 2026, at 10:09 CET
The FTSE 100 provides the relevant UK market context for AstraZeneca, whose primary listing is in London: Current FTSE 100 market coverage.
